Expert review of respiratory medicine最新文献_第10页

Unveiling the potential of lung transplantation for situs inversus. 揭示逆位肺移植的潜力。

Expert review of respiratory medicine Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.1080/17476348.2024.2447513

Yudai Miyashita, Taisuke Kaiho, Chitaru Kurihara

{"title":"Unveiling the potential of lung transplantation for situs inversus.","authors":"Yudai Miyashita, Taisuke Kaiho, Chitaru Kurihara","doi":"10.1080/17476348.2024.2447513","DOIUrl":"10.1080/17476348.2024.2447513","url":null,"abstract":"Introduction: Situs inversus is a rare congenital condition where the organs in the chest and abdomen are reversed, thus complicating surgeries such as lung transplantation. Kartagener syndrome (KS), associated with situs inversus, includes chronic sinusitis and bronchiectasis, which can progress to end-stage lung disease requiring transplantation. This review discusses the unique surgical considerations, technical challenges, and outcomes of lung transplantation in patients with situs inversus, particularly KS.Areas covered: The review highlights anatomical and physiological challenges in lung transplantation due to reversed organ positioning, requiring customized surgical approaches and intraoperative modifications. Preoperative imaging, anesthesia adjustments, and tailored surgical techniques are crucial for successful transplantation. Postoperative care focuses on managing complications such as primary graft dysfunction, infections, and anastomotic issues. Literature on survival rates, chronic lung allograft dysfunction, and quality of life is analyzed, indicating outcomes comparable to other lung transplant recipients.Expert opinion: Despite significant challenges, lung transplantation in patients with situs inversus and KS is feasible with outcomes similar to traditional cases. Advances in imaging, surgical planning, and minimally invasive techniques offer promise for improved outcomes. Ongoing research, collaboration, and ethical considerations are essential to optimizing care and expand treatment possibilities for this high-risk patient population.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"43-54"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interactions between epithelial mesenchymal plasticity, barrier dysfunction and innate immune pathways shape the genesis of allergic airway disease. 上皮间充质可塑性、屏障功能障碍和先天免疫途径之间的相互作用形成了过敏性气道疾病的发生。

Expert review of respiratory medicine Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/17476348.2024.2449079

Allan R Brasier

{"title":"Interactions between epithelial mesenchymal plasticity, barrier dysfunction and innate immune pathways shape the genesis of allergic airway disease.","authors":"Allan R Brasier","doi":"10.1080/17476348.2024.2449079","DOIUrl":"10.1080/17476348.2024.2449079","url":null,"abstract":"Introduction: In genetically predisposed individuals, exposure to aeroallergens and infections from RNA viruses shape epithelial barrier function, leading to Allergic Asthma (AA). Here, activated pattern recognition receptors (PRRs) in lower airway sentinel cells signal epithelial injury-repair pathways leading to cell-state changes [epithelial mesenchymal plasticity (EMP)], barrier disruption and sensitization.Areas covered: 1. Characteristics of sentinel epithelial cells of the bronchoalveolar junction, 2. The effect of aeroallergens on epithelial PRRs, 3. Role of tight junctions (TJs) in barrier function and how aeroallergens disrupt their function, 4. Induction of mucosal TGF autocrine loops activating type-2 innate lymphoid cells (ICL2s) leading to Th2 polarization, 5. How respiratory syncytial virus (RSV) directs goblet cell hyperplasia, and 6. Coupling of endoplasmic reticulum (ER) stress to metabolic adaptations and effects on basal lamina remodeling.Expert opinion: When aeroallergens or viral infections activate innate immunity in sentinel cells of the bronchoalveolar junction, normal barrier function is disrupted, promoting chronic inflammation and Th2 responses. An improved mechanistic understanding of how activated PRRs induce EMP couples with TJ disruption, metabolic reprogramming and ECM deposition provides new biologically validated targets to restore barrier function, reduce sensitization, and remodeling in AA.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"29-41"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the need for better management of pleural infections in low- to middle-income countries. 解决中低收入国家更好地管理胸膜感染的需要。

Expert review of respiratory medicine Pub Date : 2025-01-01 Epub Date: 2025-01-14 DOI: 10.1080/17476348.2025.2453117

Jane A Shaw, Coenraad F N Koegelenberg

引用次数: 0

Achieving sustained remission in severe asthma: goals, challenges, issues and opportunities. 实现严重哮喘的持续缓解：目标、挑战、问题和机遇。

Expert review of respiratory medicine Pub Date : 2025-01-01 Epub Date: 2025-01-05 DOI: 10.1080/17476348.2024.2449080

Alessandro Vatrella, Angelantonio Maglio

引用次数: 0

Radon exposure as an occupational risk factor for lung cancer in conventional workplaces. An overview. 氡暴露作为传统工作场所肺癌的职业风险因素。概述。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-22 DOI: 10.1080/17476348.2024.2444363

Lucía Martin-Gisbert, Guadalupe García, Ana Teijeiro, Alberto Ruano-Ravina

{"title":"Radon exposure as an occupational risk factor for lung cancer in conventional workplaces. An overview.","authors":"Lucía Martin-Gisbert, Guadalupe García, Ana Teijeiro, Alberto Ruano-Ravina","doi":"10.1080/17476348.2024.2444363","DOIUrl":"10.1080/17476348.2024.2444363","url":null,"abstract":"Introduction: Radon gas has been a declared human carcinogen for more than 30 years and has been causally associated with lung cancer. Studies have shown a linear relationship between residential radon exposure and lung cancer risk.Areas covered: Initially, this risk was subjected to cohorts of underground miners and then in case-control studies in the general population.While the evidence on residential radon exposure and lung cancer risk is extensive, there is little evidence on occupational radon exposure in conventional workplaces. Studies estimating radon-attributed mortality and prevalence also consider only residential radon exposure.Expert opinion: As individuals are also exposed to radon in the workplace, further studies should incorporate an integrated assessment of radon exposure, including both residential and occupational exposure.The European Council Directive established specifications for occupational exposure to radon, indicating the reference level and making it mandatory to measure radon in the workplace. EU countries have adopted national legislation incorporating this framework, some relatively recently. These regulations create an unprecedented situation for previously and currently exposed workers. It is important that the legislation on the determination of radon concentrations in the workplace is rigorously enforced and introduced in countries where this is not yet the case.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1041-1046"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing protective ventilation in adults with acute brain injury-challenging misconceptions and prioritizing neuromonitoring. 优化急性脑损伤成人的保护性通气——挑战误解，优先进行神经监测。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1080/17476348.2024.2438088

Robin L Goossen, Marcus J Schultz, David M P van Meenen, Janneke Horn, Patricia R Rocco, Chiara Robba

引用次数: 0

Inhaled immunosuppressants after lung transplantation -real potential to enhance patient outcomes. 肺移植术后吸入免疫抑制剂--提高患者疗效的真正潜力。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1080/17476348.2024.2434152

Gregory I Snell, Samantha L Ennis, Bronwyn J Levvey

引用次数: 0

Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population. 在COPD患者中，奥替特罗/噻托溴铵和维兰特罗/乌莫列地铵的比较疗效：一项与美国医疗保险人群中新用户队列研究相匹配的高维倾向评分

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-12-30 DOI: 10.1080/17476348.2024.2446598

Chintal H Shah, Robert M Reed, Linda Wastila, Eberechukwu Onukwugha, Mathangi Gopalakrishnan, Zafar Zafari

{"title":"Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US medicare population.","authors":"Chintal H Shah, Robert M Reed, Linda Wastila, Eberechukwu Onukwugha, Mathangi Gopalakrishnan, Zafar Zafari","doi":"10.1080/17476348.2024.2446598","DOIUrl":"10.1080/17476348.2024.2446598","url":null,"abstract":"Background: Two long-acting muscarinic antagonist inhaler fixed dose combinations (olodaterol/tiotropium (OLO/TIO) and vilanterol/umeclidinium (VI/UMEC)) have once-a-day dosing for managing chronic obstructive pulmonary disease (COPD). This study aimed to compare clinical effectiveness of these inhalers in terms of ability to prevent severe COPD exacerbations in a United States Medicare population.Research design and methods: Using nationally representative Medicare data (2013-2019), we employed a new user, active comparator design among beneficiaries aged 65 years and older with COPD. The outcome of interest was time to first occurrence of a severe COPD exacerbation. To ensure comparability between the groups, we performed 1:3 (OLO/TIO:VI/UMEC) nearest neighbor matching based on their high-dimensional propensity scores.Results: The study included 2,263 OLO/TIO new initiators matched to 6,789 VI/UMEC new initiators. The incidence rate of the first severe COPD exacerbation was 40.8 per 100 person-years among new initiators (39.9 per 100 person-years for OLO/TIO, 41.1 per 100 person-years for VI/UMEC). The adjusted hazard ratio of the time to first COPD exacerbation was 0.948 (95% Confidence interval: 0.813-1.105) for individuals initiating OLO/TIO versus VI/UMEC.Conclusion: We did not find a statistically significant difference between the OLO/TIO and VI/UMEC new users in terms of time to first severe exacerbation among Medicare COPD patients aged 65 or older.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1113-1120"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on endobronchial valve therapy for severe emphysema: real world data and special indications. 严重肺气肿的支气管内瓣膜治疗最新进展：真实世界的数据和特殊适应症。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/17476348.2024.2431522

Tadashi Sakaguchi, Jorine E Hartman, Dirk-Jan Slebos

{"title":"An update on endobronchial valve therapy for severe emphysema: real world data and special indications.","authors":"Tadashi Sakaguchi, Jorine E Hartman, Dirk-Jan Slebos","doi":"10.1080/17476348.2024.2431522","DOIUrl":"10.1080/17476348.2024.2431522","url":null,"abstract":"Introduction: Bronchoscopic lung volume reduction (BLVR) using one-way endobronchial valves (EBV) is a guideline therapy for patients with severe emphysema without interlobar collateral ventilation, based on solid results from multiple randomized clinical trials (RCTs). However, whether its efficacy and safety in real-world clinical settings are comparable to those observed in RCTs has not been fully investigated. Additionally, recent reports on EBV therapy have focused on specialized populations (e.g. very low FEV1, very low DLCO) that were not represented in the RCTs.Areas covered: We have summarized the efficacy and safety of the publications on BLVR with EBVs in real-world settings and in specialized populations, and have discussed these findings in relation to the RCTs data.Expert opinion: The benefits of BLVR with EBVs have effectively translated into real-world clinical practice with a tolerable safety profile. These benefits and acceptable safety profile were also observed in specialized populations not fully represented in RCTs. We believe it is crucial to establish a nationwide registry in each country to keep track of outcome for quality and consistency, and to have a multidisciplinary COPD team discussion in each treating institution to keep on ensuring the successful clinical practice of BLVR with EBVs.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1003-1011"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute respiratory failure in adult patients with acute myeloid leukemia. 急性髓性白血病成人患者的急性呼吸衰竭。

Expert review of respiratory medicine Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/17476348.2024.2433554

Dara Chean, Alexis Maillard, Amira Benattia, Sofiane Fodil, Elie Azoulay

{"title":"Acute respiratory failure in adult patients with acute myeloid leukemia.","authors":"Dara Chean, Alexis Maillard, Amira Benattia, Sofiane Fodil, Elie Azoulay","doi":"10.1080/17476348.2024.2433554","DOIUrl":"10.1080/17476348.2024.2433554","url":null,"abstract":"Introduction: Patients with acute myeloid leukemia (AML) are at high risk of developing life-threatening complications. It is estimated that a quarter of adult patients diagnosed with AML will require admission to the intensive care unit (ICU) at least once during their disease. Acute respiratory failure (ARF) is the main reason for ICU admission and is associated with high mortality rates, depending on the etiology of ARF.Areas covered: In this population, the high prevalence of severe pulmonary infections highlights the importance of immunosuppression caused by the disease and its treatment. In the early stages of the disease, in addition to pneumonia, which should be systematically sought, leukemia-specific lung involvement (leukostasis, leukemic pulmonary infiltration, and acute lysis pneumopathy) is an important cause of ARF in this population, representing up to 60% of cases. This review aims to help understand the pathophysiology and management of leukemia-specific lung involvement, based on the most contemporary literature.Expert opinion: The number of AML patients requiring ICU care is expected to increase. AML patients admitted to the ICU for ARF have a high mortality rate, but survivors have encouraging long-term outcomes. Future research will focus on improving risk stratification, cytoreduction, oxygenation strategies, and diagnostic techniques for ARF.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"963-974"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0